Nanexa Q2 FY26 operating loss widens to SEK 13.88 million; net sales fall to SEK 1.65 million

Reuters2026/08/27 06:05

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Nanexa posted Q2 operating loss of SEK 13.88 million, worsening from SEK 5.24 million a year earlier.
Net sales fell to SEK 1.65 million from SEK 2.71 million, reflecting no income from the Novo Nordisk exclusivity deal.
Net loss widened to SEK 14.03 million from SEK 5.9 million; cash flow for the quarter declined to SEK -20.47 million.
Cash and short-term investments totaled SEK 52.56 million at June 30; management sees runway into Q2 2027.
Modernа collaboration progressed with testing of coated mRNA particles; active talks continue to outlicense PharmaShell for obesity and type 2 diabetes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanexa AB published the original content used to generate this news brief on August 27, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Nanexa Q2 FY26 operating loss widens to SEK 13.88 million; net sales fall to SEK 1.65 million

You may also like

Crypto prices